Skip to main content
. Author manuscript; available in PMC: 2016 Jan 5.
Published in final edited form as: Eur J Pharmacol. 2014 Oct 30;746:106–114. doi: 10.1016/j.ejphar.2014.10.042

Fig 6. Electrophoretic mobility shift assay in Ang II treated cells.

Fig 6

Electrophoretic mobility shift assay (EMSA) analysis was performed with nuclear extracts from control BAECs or Ang II treated BAECs (0.1 µM, 30 mins). Ang II treatment enhanced formation of binding complex between nuclear extracts with oligonucleotide containing the wild-type AP-1 site compared to untreated BAECs (Left panel). No specific complex formation was observed for either nuclear extracts with the oligonucleotide containing the mutant AP-1 sequence (Right panel). Result shown is representative of three independent experiments. n=3.